#Neisseria Gonorrhoeae Infections Treatment Market Trends | Explore Tumblr Posts and Blogs

pharmaceuticals88 · 2 years

Text

Neisseria Gonorrhoeae Infections Treatment Market 2022 Is Booming Globally | Top Leading Players are Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA

The Neisseria Gonorrhoeae Infections Treatment Market Size by 2029, exhibiting a CAGR of 4.6% during 2022-2029

Neisseria Gonorrhoeae Infections Treatment Market Overview

The Neisseria Gonorrhoeae Infections Treatment Market report is a comprehensive overview of the market, including a review of its major segments. Neisseria Gonorrhoeae Infections Treatment Market are developed after thorough primary and secondary studies. By speaking with industry experts and collecting their data, in-depth market data is produced. The report provides a thorough account of many market factors, including trends, segmentation, growth prospects, chances, difficulties, and competitive analyses.

Get a Sample copy of the report:

List of Key Players Of Neisseria Gonorrhoeae Infections Treatment Market Report:

Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co., Inc., Paratek Pharmaceuticals, Inc., Recce Pty Ltd, Redx Pharma Plc, Sarepta Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd

Key Segments Covered in Neisseria Gonorrhoeae Infections Treatment Market

By Type, it is segmented into

Cribrostatin-6

Dalbavancin

Debio-1453

Gepotidacin Mesylate

Others

By Application, it is segmented into

Clinic

Hospital

Others

Competitive Landscape

Neisseria Gonorrhoeae Infections Treatment Market are showing an increasing amount of interest in creating unique products. In addition, several companies are collaborating, merging, and acquiring one another. In the upcoming years, all of these initiatives are anticipated to drive the global Neisseria Gonorrhoeae Infections Treatment Market to new heights.

The Neisseria Gonorrhoeae Infections Treatment Market Regional Analysis Covers

– North America: United States, Canada, and Mexico. – South & Central America: Argentina, Chile, and Brazil. – Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. – Europe: UK, France, Italy, Germany, Spain, and Russia. – Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Get in Touch with Us: - Phone No.+1 (704) 266-3234

Mail to: [email protected]

#Neisseria Gonorrhoeae Infections Treatment Market Research #Neisseria Gonorrhoeae Infections Treatment Market Forecast #Neisseria Gonorrhoeae Infections Treatment Market Size #Neisseria Gonorrhoeae Infections Treatment Market Share #Neisseria Gonorrhoeae Infections Treatment Market Trends #Neisseria Gonorrhoeae Infections Treatment Market Overview

0 notes

trendingresearchreports · 1 year

Text

0 notes

captain-kartikj · 5 years

Text

Global Neisseria Gonorrhoeae Infections Treatment Market 2019 Analysis and Forecasts to 2025

Global Neisseria Gonorrhoeae Infections Treatment Market Research Report 2019” new report to its research database. The report spread across 109 pages with multiple tables and figures in it.

The global Neisseria Gonorrhoeae Infections Treatment market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.

This report focuses on…

View On WordPress

#Market trends #Neisseria Gonorrhoeae Infections Treatment #Neisseria Gonorrhoeae Infections Treatment Industry #Neisseria Gonorrhoeae Infections Treatment Industry Analysis #Neisseria Gonorrhoeae Infections Treatment Market #Neisseria Gonorrhoeae Infections Treatment Market Analysis #Neisseria Gonorrhoeae Infections Treatment Market Growth #Neisseria Gonorrhoeae Infections Treatment Market Share #Neisseria Gonorrhoeae Infections Treatment market trends

0 notes

elisamuel412-blog · 2 years

Link

0 notes

bhandvalkar94 · 3 years

Text

Global Antibiotic Resistance Market to Grow at 4% CAGR during 2021-2029

When microbes evolve biological mechanisms that can protect them from elimination by antimicrobial, the danger of antimicrobial resistance (AMR) is visible. AMR are drug-resistant pathogens whose spread is a growing public health concern in many countries. The growth of resistant bacteria usually happens due to overuse of antibiotics, or due to their use being different from what has been prescribed. This renders antibiotics less effective or ineffective. It is believed that by 2050, AMR infections may cause 10 million deaths annually. Increase in hospitalizations and increasing use of antibiotics in COVID-19 treatment are expected to further exacerbate AMR. Hence, the market for antibiotic resistance research and medicines useful for treatment is expected accelerate in the near future.

Tuberculosis (TB) is one of the most dangerous infectious diseases from a single infectious agent and its virus has developed significant antibiotic resistance in the modern times. Multidrug-resistant TB (MDR-TB) is considered a global public health emergency by the World Health Organization. According to 2017 estimates, 465,000 cases of TB were estimated worldwide. 38% people were eligible for MDR/Rifampicin-resistant (RR)-TB. 57% of MDR/RR-TB cases received successful treatment. Mylan has also secured approval from Drugs Controller General of India (DCGI) for Pretomanid, which is useful for treatment for highly drug-resistant forms of tuberculosis. Johnson & Johnson has been in the business of developing and responsibly deploying innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.

Request a sample Copy@

https://www.absolutemarketsinsights.com/request_sample.php?id=876

The major factor driving the growth of global antibiotic resistance market is the growing prevalence of hospital-acquired infections. Antibiotic resistant bacteria can spread from person to person in the community. Implementing precautionary infection control procedures can minimize spread of such bacteria in hospitals. From person to person, usually this infection spreads from contact with either contaminated hands of hospital staff, or contaminated surfaces such as door handles, over-bed tables and call bells. Sometimes it also spreads due to contact with contaminated equipment that includes stethoscopes and blood pressure cuffs.

Strategic investments coupled with favorable initiatives by regulatory authorities showcases significant opportunities for the growth of global antibiotic resistance market over the period of next eight years. The Food and Drug Administration (FDA) of the United States of America (USA) and the Centers for Disease Control (CDC) in USA have launched several initiatives to help address antibiotic resistance. FDA is also encouraging new research into effective diagnostic tests, antibiotic regimens, and vaccines. Under qualified infectious disease product (QIDP) program, which is meant to encourage antibiotic development, FDA has also approved new and innovative antibiotics for resistant infections. Such antibiotics include Arikayce (amikacin liposome inhalation suspension), Baxdela (delafloxacin), Nuzyra (omadacycline), Pretomanid, Recarbrio (cilastatin, imipenem, & relebactam), Xerava (eravacycline), and Xepi (ozenoxacin).

The different variants of the coronoavirus has had severe impact on patients. Increased dosage of antibiotics are being prescribed to COVID patients who developed co-infections (bacterial with coronavirus). Increased investments into research and development initiatives towards adequate treatment of the same is anticipated to propel the growth of global antibiotic resistance market over the forecast period.

Enquiry Before Buying@

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=876

Key Findings of the Report:

· The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029).

· The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.

· The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.

· Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.

· In 2020, North America dominated the global antibiotic resistance market. Availability of advanced medical sector, increasing prevalence of infectious diseases, presence of major market players, numerous drug launches in the market, and rising growth in the pharmaceutical sector amongst other factors have contributed towards the region’s highest share. Infectious Diseases Society of America (IDSA) has approved the use of many new drugs that are expected to offer successful treatment against bacteria and viruses that have developed antibiotic resistance.

· Some of the major players operating in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.

Request for Customization@

https://www.absolutemarketsinsights.com/request_for_customization.php?id=876

Global Antibiotic Resistance Market:

· By Resistant Bacteria Type

o Pseudomonas Aeruginosa

o Clostridioides difficile (C. difficile)

o Carbapenem-resistant Enterobacteriaceae (CRE)

o Streptococcus pneumoniae (S. pneumoniae)

o Acinetobacter

o Vancomycin-resistant Enterococci (VRE)

o Mycobacterium Tuberculosis (TB)

o Neisseria gonorrhoeae (N. gonorrhoeae)

o Others

· By Disease Indication

o Complicated Urinary Tract Infections (cUTI)

o Complicated Intra-Abdominal Infections (cIAI)

o Community-Acquired Bacterial Pneumonia (CABP)

o Acute Skin and Skin Structure Infections (ABSSSI)

o Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)

o Sepsis

o Clostridium Difficile (C. difficile) Infections

o Others

· By Drug Class

o Antimycobacterials

o Fluoroquinolones

o Oxazolidinones

o Tetracyclines

o Penicillins

o Antifolates

o Combination Treatment

o Others

· By Route of Administration

o Oral

o Topical

o Intramuscular

o Intravenous (IV)

· By End Use

o Home Care

o Healthcare Facilities

o Others

· By Region

o North America

§ U.S.

§ Canada

§ Mexico

§ Rest of North America

o Europe

§ France

§ The UK

§ Spain

§ Germany

§ Italy

§ Nordic Countries

· Denmark

· Finland

· Iceland

· Sweden

· Norway

§ Benelux Union

· Belgium

· The Netherlands

· Luxembourg

§ Rest of Europe

o Asia Pacific

§ China

§ Japan

§ India

§ New Zealand

§ Australia

§ South Korea

§ Southeast Asia

· Indonesia

· Thailand

· Malaysia

· Singapore

· Rest of Southeast Asia

§ Rest of Asia Pacific

o Middle East & Africa

§ Saudi Arabia

§ UAE

§ Egypt

§ Kuwait

§ South Africa

§ Rest of Middle East & Africa

o Latin America

§ Brazil

§ Argentina

§ Rest of Latin America

For More Information Click@ https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876

About Us: Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Company: Absolute Markets Insights Email id: [email protected] Phone: +91-740-024-2424 Contact Name: Shreyas Tanna The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016 Website: https://www.absolutemarketsinsights.com/

0 notes

blueweave · 3 years

Text

United States Gonorrhea Therapeutics Market is Expected to Reach USD 892.3 Million by 2031 | BlueWeave

According to BlueWeave Consulting, the United States gonorrhea therapeutics market is estimated to have reached USD 456.8 million in 2020 and is further projected to reach USD 892.3 million by 2027, growing at a CAGR of 6.2% during 2021-2031 (forecast period). Preference for NAATs over traditional cultures has grown significantly in recent years owing to their improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. Such increased availability and adoption of testing modalities are driving the demand for gonorrhea therapeutics. The increasing prevalence of gonorrhea coupled with the rising public awareness about STDs (Sexually-Transmitted Diseases), and advances in relevant diagnostic methods, are the key growth determinants of the gonorrhea therapeutics market.

Growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives

The rise in patient awareness, such as education campaigns and increasing government initiatives, are expected to show lucrative opportunities for market players. Moreover, the rising population having increased casual sex partners is also feeding market growth. The Centers for Disease Control and Prevention (CDC) assesses that there are about 20 million new STD diseases each year—almost half of them among young people ages 15 to 24. Along with the government, multiple non-profit organizations are also organizing awareness campaigns against sexually transmitted diseases. For instance, CDC organized an STD Awareness Week from April 12- 18, 2020.

Hefty financial allocations for R&D activities

Currently, there is no vaccine for the treatment of Gonorrhea due to which companies are heavily investing to gain a competitive edge and to hold the market position. For instance, GSK started a phase III clinical program investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (uUTI, also known as acute cystitis) and urogenital gonorrhea (GC). Entasis Therapeutics at the World Anti-Microbial Resistance Congress has registered the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of uncomplicated gonorrhea.

Request to Download Free Sample Report: https://www.blueweaveconsulting.com/united-states-gonorrhea-therapeutics-market/report-sample

Injectables segment occupy the major share of the United States Gonorrhea Therapeutics market

Based on the route of administration, the United States gonorrhea therapeutics market is segregated into oral & injectable. In 2019, the Injectables market segment recorded a major share in the market. Due to emerging strains of drug-resistant Neisseria, the Centers for Disease Control and Prevention recommends that uncomplicated gonorrhea be treated with the antibiotic ceftriaxone given as an injection with oral azithromycin, erythromycin, clarithromycin, azithromycin, and roxithromycin are the most recommended macrolides. Tetracycline is an antibiotic that fights infection caused by bacteria such as Neisseria gonorrhea and is the second primary drug after macrolides.

United States Gonorrhea Therapeutics market: Regional insights

Growing awareness about sexually transmitted diseases and the available cure for the same is supposed to help newer diagnostic tools for gonorrhea over the traditional method of detection. Rapidly changing lifestyles and the involvement of multiple sex partners is the factor anticipated to boost the market in the future. Though weak healthcare structure and low disposable incomes may hamper the market in the country, the market growth rate is expected to stabilize owing to the growing number of hospitals, commercial labs, and newer diagnostic techniques with cost-saving and faster procedures.

The leading players” in the United States gonorrhea therapeutics market include GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher, Abbott, Becton Dickinson and Company, F. Hoffmann-La Roche Ltd., Alopexx Pharmaceuticals, Melinta Therapeutics & other prominent players. These industry players implement various strategies such as mergers & acquisitions, partnerships, and new product launches to enhance profitability and company growth.

Don’t miss the business opportunity of the Gonorrhea Therapeutics market. Consult our analysts, gain crucial insights, and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the United States gonorrhea therapeutics market size & forecast. The report promises to provide recent technology trends of the gonorrhea therapeutics market and industry insights that help decision-makers to make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

BlueWeave Consulting Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

[email protected]

https://www.linkedin.com/company/blueweaveconsulting/

#United States Gonorrhea Therapeutics Market #United States Gonorrhea Therapeutics Market Size #United States Gonorrhea Therapeutics Market SHare #United States Gonorrhea Therapeutics Market Forecast #United States Gonorrhea Therapeutics Market Growth

0 notes

ajjpatil · 4 years

Text

Neisseria Gonorrhoeae Infections Treatment Market Growing Demand 2019 to 2025 | Allergan Plc, BioDiem Ltd, Biolytics Pharma

The Global Neisseria Gonorrhoeae Infections Treatment Market report offers insights about the various factors driving the popularity and its features. A comprehensive analysis collected to provide the latest insights into the Global Neisseria Gonorrhoeae Infections Treatment market's acute features. Neisseria Gonorrhoeae Infections Treatment Market explores the effective study of high-leading players in various sectors of industry such as opportunities, size, growth, technology, demand and trend. Neisseria Gonorrhoeae Infections Treatment also offers market-specific statistics on the state of suppliers, a valuable source of advice, guidance for businesses and those involved in the industry.

DOWNLOAD FREE SAMPLE REPORT at: https://www.researchkraft.com/request-sample/1019288

Key Manufacturers Diagnosis:

Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Paratek Pharmaceuticals Inc., Recce Pty Ltd, Redx Pharma Plc, Sarepta Therapeutics Inc., Sumitomo Dainippon Pharma Co. Ltd

The Market is Segmented by Product Type as Follows:

Cribrostatin-6

Dalbavancin

Debio-1453

Gepotidacin Mesylate

Others

Breakdown Information by Application and Market Share and Growth, Covering:

Clinic

Hospital

Others

Each geographic segment of the market was independently examined with pricing and analysis, distribution, and demand data for geographic market notably:

Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey, GCC Countries

Get it at the Discounted price: https://www.researchkraft.com/check-discount/1019288

The Global Neisseria Gonorrhoeae Infections Treatment Market Research Report is a comprehensive market research report that includes an introduction to new trends that can guide businesses in the industry to understand the market and make the strategies for their business growth. The Neisseria Gonorrhoeae Infections Treatment research report looks at market size, industry share, key growth drivers, major segments, and CAGR. The Neisseria Gonorrhoeae Infections Treatment report will answer questions about current market advances and the competitive scope, opportunities, costs and more. The report also scrutinizes in-depth the key international players on the Neisseria Gonorrhoeae Infections Treatment market.

The latest advancements in the Neisseria Gonorrhoeae Infections Treatment industry and changing market trends are key drivers for huge growth. This study also lists the risk factors that will have a direct impact on the global Neisseria Gonorrhoeae Infections Treatment market in the coming years. The types, applications, and key regions of the revenue-generating Neisseria Gonorrhoeae Infections Treatment are assessed. This business report on Neisseria Gonorrhoeae Infections Treatment also analyzes the top countries with their market potential in those areas.

Highlights of the report:

Scrutinized driver data and restrictions affecting the Neisseria Gonorrhoeae Infections Treatment market's growth.

Provide insights into factors affecting growth in the market. Analyzing the Neisseria Gonorrhoeae Infections Treatment industry based on a variety of factors-price analysis, supply chain analysis, porter analysis of five powers etc.

Detailed analysis of the global Neisseria Gonorrhoeae Infections Treatment market's distribution channels, and consumption patterns.

Comprehensive market player assessment of Neisseria Gonorrhoeae Infections Treatment that includes strengths, weaknesses, opportunities and threats.

Extensive detail on recent Neisseria Gonorrhoeae Infections Treatment R&D ventures across different regions and end-use industries.

Updated insights into trends affecting the growth of the Neisseria Gonorrhoeae Infections Treatment market, including ecological preservation, and regulatory standards.

Enquire more about the report at: https://www.researchkraft.com/send-an-enquiry/1019288

#Neisseria Gonorrhoeae Infections Treatment Market

0 notes

morganbelarus · 6 years

Text

We Have Some Bad News And Some Good News About Gonorrhea

Scientists have been issuing increasingly urgent warnings about the dangers of antibiotic-resistant gonorrhea, but it seems that may not be the only thing we have to fear from “the clap”. A team at the Melbourne Sexual Health Center have found evidence saliva may play a role in transmitting the bacterium, which would open up the possibility that even kissing may be unsafe. If you thought that might ruin your day, the good news is that antiseptic mouthwashes may prevent the disease's spread.

The bacterium Neisseria gonorrhoeae has been interfering with people's sex lives for centuries. Some men, and about half of women, whose genitals become infected show no symptoms, greatly increasing the danger they will pass it on to others. Less fortunate women can suffer pelvic inflammatory disease and find sex becoming painful. For men, the most common symptom is a burning sensation during urination, but urinary infection also raises the risk of liver disease, some cancers and a range of other rare, but very nasty, outcomes.

Once a common disease, gonorrhea’s frequency dropped markedly with the invention of antibiotics but made a comeback to peak in the 1970s. Increased use of condoms to protect against HIV had the beneficial side effect of causing rates of other sexually transmitted infections, gonorrhea included, to plunge dramatically. However, we are once again seeing a rising trend.

Professor Kit Fairley of Monash University thinks our efforts to impede the bacterium's spread may have been hampered by misunderstanding how it is transmitted. He leads a team that has published a string of papers slowly building evidence that saliva is much more important than has been recognized, something we will need to come to grips with if we are to stop it.

As well as the urinary tract, gonorrhea can infect the throat or anus. Symptoms in both are rare, and it usually clears within a few months or year depending on the site. These infections are rarely a problem on their own, but represent a major transmission risk. Painful urinary infections quickly drive people to get treatment, but without symptoms, most infections in the throat and anus go untreated, and can then be transferred to others. However, Fairley thinks sexual health experts have been misunderstanding how this occurs.

Where conventional transmission models blame oral and anal sex for transmission, Fairley was struck by a surprising number of men coming to the clinic who said they had always used a condom during anal sex.

A single individual might be lying or forgetful but to Fairley, the cases were too common to ignore. Gonorrhea is often found in saliva, but in recent times this was not thought to be important for transmission. In the journals Emerging Infectious Diseases and Sexually Transmitted Infections, Fairley proposes this is wrong. He suggests the use of saliva as a lubricant during anal sex could account for much of the pattern of gonorrhea transmission the clinic has observed. Add in transmission from throat to throat through kissing, and to the genitals through oral sex, and the rest of the story falls into place.

Fairley told IFLScience a peck on the lips is unlikely to be a danger, but deep kissing with tongues in one another's mouths is a different matter. Unfortunately, studies on gonorrhea transmission seldom even ask how many partners someone has kissed.

Even before anti-retroviral drugs, many nations brought the AIDS crisis under control, not by persuading people not to have sex, but by boosting condom use. Fairley hopes mouthwash could be gonorrhea's equivalent. Listerine was initially marketed against gonorrhea, before gaining a more profitable application for bad breath, Fairley's co-author Dr Tim Read told IFLScience. The clinic is about to start a large-scale trial testing the effectiveness of mouthwash for preventing gonorrhea's transmission.

For reasons that are not fully understood, gonorrhea is most frequent in developed countries among men who have sex with men. However, rates of heterosexual transmission are rising, and the bacterium may soon be, once again, a much more widespread problem. If this combines with antibiotic-resistance, we could be facing the return of a disease thought to have been put behind us 60 years ago.

More From this publisher : HERE ; This post was curated using : TrendingTraffic

=> *********************************************** Read Full Article Here: We Have Some Bad News And Some Good News About Gonorrhea ************************************ =>

We Have Some Bad News And Some Good News About Gonorrhea was originally posted by 16 MP Just news

#16 MP Just news

0 notes

sapanas · 4 years

Text

Molecular Diagnostics Market 2020 Leading Growth Drivers, Emerging Audience, Emerging Factors, Segments

Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Molecular Diagnostics Market and demographic challenges, showed how it could move forward in the coming years.

Molecular Diagnostics Market Top Vendors

The top vendors in the global molecular diagnostics market include Hologic, Inc. (U.S.), QIAGEN N.V. (the Netherlands), Grifols (Spain), Bio-Rad Laboratories, Inc. (US), Abbott (U.S.), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (U.S.), Cepheid (U.S.), BD (U.S.), bioMérieux SA (France), Beckman Coulter Inc. (U.S.), and others.

Molecular Diagnostics Market Outlook

The latest study conducted by Market Research Future (MRFR) envisions a promising future for the global molecular diagnostics market, which is poised to surge at a brilliant CAGR of 9.6% during the forecast period (2017-2023).

Molecular diagnostic tests are highly useful in detecting certain sequences in DNA or RNA, which include single nucleotide polymorphism (SNP), rearrangements, deletions, insertions, as well as others so the disease can be further diagnosed. Such cumulative techniques are used for the analyzation of biological markers at the molecular level, like proteome and genome. Furthermore, such techniques can also be used for diagnosing various infectious diseases, cancer, along with many other conditions, in addition to checking the genetic predisposition to a disease.

Read more news on: https://www.medgadget.com/2020/08/coronavirus-covid-19-impact-on-molecular-diagnostics-market-share-2020-research-report-global-size-upcoming-trends-industry-growth-key-companies-new-developments-demand-in-india.html

Molecular Diagnostics Market Growth Drivers and Key Barriers

The relentlessly expanding geriatric population around the world is expected to render tremendous positive impact on the growth of the molecular diagnostics market over the given timeframe. This is true as aging radically augments the risk of infectious and chronic conditions which can be taken care of better when diagnosed at an initial stage of development. Also, United Nations forecasts that the global geriatric population is set to expand from the value of 962 million in 2017 to 2.1 billion by the year 2050. This drastic increase in the elderly population base coupled with the consequent surge in demand for early and improved diagnostic methods will be highly instrumental in the growth of the molecular diagnostics market in the near future.

In addition, the aging population generally opt for non-hospital settings like home care on account of the comfort factor as well as the economic benefits associated with this kind of setting. This factor leads to the increased need for point of care diagnostic testing that offer rapid and accurate results.

Besides, numerous companies are making immense efforts for developing point of care molecular diagnostic tests in order to widen their customer base and also rise above their current market position. They also enter into partnerships and collaborations with other companies in a bid to soar above the intense competition the market is characterized by. Accelerated demand for point of care molecular diagnostic supports the development of the molecular diagnostics market as well, laying a strong foundation for further expansion of the market size in the foreseeable future. Illustrating the efforts put in by the players, Sona Nanotech Inc., in March 2019, collaborated with a UK medical diagnostics company for developing a highly sensitive point of care diagnostic tests that are highly useful for diagnosing various infectious diseases.

Molecular Diagnostics Market Opportunities

With the alarming rise in the occurrence of sexually transmitted infections (STIs) like Chlamydia trachomatis and Neisseria gonorrhoeae, the frequent need of diagnostics is equally on the rise around the world. Therefore, the demand for molecular diagnostics has been quite decent in the past couple of years. In short, the increasing adoption of molecular diagnostics in the wake of increasing STIs across the globe will present countless growth opportunities to the molecular diagnostics market.

Molecular Diagnostics Market Segmentation

The market for molecular diagnostics is segmented on the basis of techniques, applications and end users.

The various techniques in the global market are Polymerase chain reaction (PCR) and real-time PCR, fluorescence in-situ hybridization, microarray, transcription-mediated amplification, and next-generation sequencing.

Application-wise, the market caters to infectious diseases, oncology, blood screening, genetic testing, pharmacogenomics, human leukocyte antigen typing, coagulation, others.

Lastly, the end users that are mentioned in the report are hospitals, diagnostic laboratories, academics and research institutions.

Molecular Diagnostics Market Regional Outlook

The regional analysis done for the global molecular diagnostics market is for the key regions of America, Asia Pacific, Europe, as well as Middle East & Africa.

Based on the geographical distribution, America has attained the substantial share of the global molecular diagnostics market, with Europe and Asia Pacific right behind. Growing prevalence of chronic diseases along with a number of cancer types, and massive investment in research sector for the treatment of diseases has elevated the market position of molecular diagnostics at a global level. The constant prediction of the ever-increasing range of infectious diseases like HIV and hepatitis contribute to the market expansion in the region. Apart from this, a swelling demand for biomarkers that are used for rapid diagnosis will auger well with the regional market growth in the near future.

Europe is steadily catching up with America, amassing the second largest share of the global market on account of the elevated demand for biomarker test for diagnosing cardiovascular diseases, especially amongst the obese people. The molecular diagnostics market in the region observes strong growth on the back of the accelerated demand for advanced molecular diagnostic products.

However, it is the region of Asia Pacific that has catapulted right among the strong contenders in the global market, by growing at the fastest rate. The strong presence of growing number of low budget hospitals and clinics along with a massive population base has resulted in the lavish growth of the market in Asia Pacific.

Middle East & Africa will be noting a rather restricted growth in the global market because of the lack of awareness among the general mass, as well as due to the limited development of the medical industry.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171

Molecular Diagnostics Industry Developments

February 2019 – Co-Diagnostics, Inc. has recently launched its first multi-disease diagnostic which was built by using their patented CoPrimer design platform. This diagnostic test can be used for dengue, chikungunya and Zika, which was developed to cater to the market demand for a cost-effective and highly-accurate diagnostic tool for all the three diseases.

#Molecular Diagnostics Market #Molecular Diagnostics Market Size #Molecular Diagnostics Market Share #Molecular Diagnostics Market Growth #Molecular Diagnostics Market Trends #Molecular Diagnostics Market Analysis

0 notes

sdmr123 · 4 years

Link

Report Scope:

The Global Neisseria Gonorrhoeae Infections Treatment Market report scope covers the in-depth business analysis considering major market dynamics, forecast parameters, and price trends for the industry growth. The report forecasts market sizing at global, regional and country levels, providing comprehensive outlook of industry trends in each market segments and sub-segments from 2017 to 2024. The market segmentations include

To get a free sample report: https://www.supplydemandmarketresearch.com/home/contact/787766?ref=Sample-and-Brochure&toccode=SDMRPH787766

To get a detailed report: https://www.supplydemandmarketresearch.com/global-neisseria-gonorrhoeae-infections-treatment-market-787766

#Neisseria Gonorrhoeae Infections Treatment Market #Neisseria Gonorrhoeae Infections Treatment Market type #Neisseria Gonorrhoeae Infections Treatment Market demand #Neisseria Gonorrhoeae Infections Treatment Market report #Neisseria Gonorrhoeae Infections Treatment Market supply

0 notes

rishabh3210blog · 5 years

Text

Chlamydia Diagnosis And Treatment Market Size, Global Industry Trends and Forecast 2019-2025

Chlamydia diagnosis and treatment market are expected to grow noticeably across the globe. Chlamydia is a very common sexually transmitted disease across the globe which is caused by the bacteria known as chlamydia trachomatis. If chlamydia is left untreated for long duration it can lead to a pelvic inflammatory disease which in turn will show additional symptoms such as ectopic pregnancy, infertility, and chronic pelvic pain. According to WHO the sexually transmitted infections are increasing across the globe in recent. Chlamydia trachomatis and Neisseria gonorrhoeae are the most frequent bacteria of sexually transmitted infections and each cause approximately 106 million new infections every year. It is likely that the new infection number would be even higher as many infections are asymptomatic and remain undiagnosed.

Request a free sample of our report on Chlamydia Diagnosis And Treatment Market: https://www.omrglobal.com/request-sample/chlamydia-disease-diagnosis-treatment-market

Having sexually transmitted infections such as chlamydia alone increases the risk of getting HIV as most of the sexually transmitted infections causes sores or lesions making it easier for HIV infection to enter into the body. So, it is mandatory to treat the chlamydia starting from the proper diagnosis. There are many lab tests available for the diagnosis of chlamydia which requires the sample that may be taken from the cervix or vagina in case of women and taken from the urethra in case of men. In the case of oral sex, the sample is collected from rectum or throat.

A full report of Global Chlamydia Diagnosis And Treatment Market is available at: https://www.omrglobal.com/industry-reports/chlamydia-disease-diagnosis-treatment-market

In many countries, self-testing kits for chlamydia are also available supporting people to test themselves without intervention from any healthcare professional which is driving the chlamydia diagnosis and treatment market. These self-testing kits reduce the hassle of uncertainty among patients and in this way the access to the correct diagnosis will increase as more people will use it. Chlamydia is associated with a high level of stigma and providing self-testing kits will increase the diagnosis rate among people since most people otherwise hesitate to come forward for testing.

A company named EverlyWell, Inc. provides a test for chlamydia in which the testing kit is ordered by the patient in their home and the barcode associated with the kit is entered into the company’s website and the test sample taken at home is sent back to the company. The physicians associated with the company analyze the sample and the final result is displayed on the company’s secure platform. Using this way, the privacy of the patient is preserved, and the correct diagnosis of chlamydial can be obtained.

A key concern about the self-testing kit and diagnosis lies in its accuracy and errors in sample handling that could hamper the final diagnosis. Also, the absence of professional support can also be considered as a disadvantage as most people feel more confident when the diagnosis is done under the observation of physicians. The advancement in the testing devices like nucleic acid amplification test coupled with the increased number of individuals undergoing screening is directly implying that the number of reported chlamydia trachomatis infection is also rising.

Global Chlamydia Diagnosis and Treatment Market- Segmentation

By Diagnosis Methods

Chlamydia Culture

Urine Culture

Enzyme Immunoassays

Nucleic Acid Amplification Test

By Treatment Approach

Oral Antibiotics

Azithromycin

Doxycycline

Other

By End-User

Hospitals

Diagnostic Centers

Research Institutions

Global Chlamydia Diagnosis and Treatment Market- Segment by Region

North America

Cana

Europe

Germany

France

Spain

Italy

Rest of Europe

Asia-Pacific

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Middle East & Africa

Latin America

Visit here to know more about Chlamydia Diagnosis And Treatment Market Size.

About Orion Market Research

Orion Market Research (OMR) is an Indian market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Reports

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +1 646-755-7667, +91 780-304-0404

0 notes

bhagyashribhole123 · 5 years

Text

Global Molecular Diagnostics Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023

Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1171

Market Opportunities

Key players for Global Molecular Diagnostics Market

Several companies in the molecular diagnostics market are looking to collaborate with research institutes in order to advance their own product development programs. Recently, EZLife announced a collaboration with the UCLA to expand EGFR lung cancer assay into RUO offerings. Such collaborations are likely to be common among key players in the molecular diagnostics market.

Industry Developments

Segmental Analysis:

The market for molecular diagnostics is segmented on the basis of techniques, applications and end users.

Application-wise, the market caters to infectious diseases, oncology, blood screening, genetic testing, pharmacogenomics, human leukocyte antigen typing, coagulation, others.

Lastly, the end users that are mentioned in the report are hospitals, diagnostic laboratories, academics and research institutions.

Regional Analysis:

The regional analysis done for the global molecular diagnostics market is for the key regions of America, Asia Pacific, Europe, as well as Middle East & Africa.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]

#Molecular Diagnostics Market Molecular Diagnostics Market Report Molecular Diagnostics Market Research Molecular Diagnostics Market Outlook

0 notes

priyankaganguly-blog · 5 years

Text

Gram-negative Bacterial Infection – Review On Trending Challenges 2025

Global Gram-negative Bacterial Infection: Overview

The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.

The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection market. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the gram-negative bacterial infection market.

Global Gram-Negative Bacterial Infection Market: Snapshot

Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.

The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.

Order Brochure for more Detailed Information @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94

According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.

Global Gram-negative Bacterial Infection: Infection-type Segmentation

On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.

Global Gram-negative Bacterial Infection: Analysis of Treatment Options

In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.

Request TOC for Facts & Tables @

https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94

Global Gram-negative Bacterial Infection: Competitive Landscape

Players in the global gram-negative bacterial infection market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, gram-negative bacterial infection market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the gram-negative bacterial infection market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

#Gram-negative Bacterial Infection

0 notes

lilywhiteflower-blog · 5 years

Text

Gram-Negative Bacterial Infection Market : Prime factors anticipated piloting for the estimated period 2017-2025

Global Gram-Negative Bacterial Infection Market: Snapshot

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94

Global Gram-negative Bacterial Infection: Overview

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94

The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.

Global Gram-negative Bacterial Infection: Infection-type Segmentation

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/gram-negative-bacterial-infection-market

Global Gram-negative Bacterial Infection: Analysis of Treatment Options

Global Gram-negative Bacterial Infection: Competitive Landscape

Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.

About TMR Research

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email: [email protected]

#Global Gram-Negative Bacterial Infection Market

0 notes

coolluminaryland-blog1 · 6 years

Text

Neisseriaceae Infections Market – Trends and Growth Factors Analysis 2014 to 2020

Bacteria represent the essential class of micro-organisms that play a crucial role in the development of infection of any disease to human being and animal. Bacteria are divided into two types on the basis of gram staining test, namely; gram-positive bacteria and gram-negative bacteria. Neisseria is one of the most important genera of bacteria which form colonies on mucosal surfaces of various animals. Neisseria consists of 11 species, out of which, two are pathogenic and others are harmless. These belong to gram negative class of bacteria, since these species show negative response to gram test.The market of Neisseriaceae infections is segmented on the basis of various bacteria that belongs to the class and diseases associated with them, such as, Acinetobacter, Kingella, Neisseria, Moraxella and Oligella. Neisseria contains bacteria such as N. meningitidis, N. gonorrhoeae, N. sicca, N. flava, N. elongata, N. cinerea and others. Out of which, N. gonorrhoeae causes gonorrhea and N. meningitidis causes septicemia and meningitis. Moraxella catarrhalis causes sinusitis, otitis, and pneumonia in adults.

Read Report Overview: https://www.transparencymarketresearch.com/neisseriaceae-infections-market.html

Kingella kingae causes CNS, urinary and respiratory infections. Moreover, it is segmented on the basis of antibacterial drugs, such as, B-lactum antibiotics (Penicillin), clavulanic acid (Augmentin), aminoglycosides (Streptomycin), glycopeptides (Vancomycin), polypeptides (Bacitracin), rifamycins (Rifampicin), chloramphenicol, tetracycline and many others. In addition, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to growing prevalence of various Neisseriaceae infections and associated disease. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in the upcoming period, owing to rapidly growing prevalence and awareness about the diseases caused due to Neisseriaceae and their chronic effects.The market is expected to show a steady growth during the forecast period from 2014 – 2020. This growth is expected to be driven by many factors, such as, increasing prevalence of Neisseriaceae infections and extensive R&D practices ongoing globally. In addition, rising prevalence of infection diseases is the most important factor that drives the growth of the market to a higher end.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3572

According to the U.S. Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported in the U.S. in 2012, an increase of around 4% compared to 2011. Thus, such rising prevalence of infections is an important growth driver of the market. Further, due to extensive R&D practices, number of drugs and formulations are on the way to enter in the market during the forecast period 2014 – 2020. Some of the important pipeline products include AXD0914, Cribrostatin-6, SM-295291 and SM-369926 amongst numerous others. Additionally, due to increased incidences of homosexuality and bisexuality, the threat of gonorrhea has also increased. These factors are supported by rising awareness about the infections and diseases and increasing medical expenditure. Owing to these, the market is expected to grow at steady rate. On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to certain extent.Some of the major players engaged in R&D and commercialization of the products in the market include Basilea Pharmaceuticals Ltd., AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Aphios Corporation, Pfizer, Inc., GSK plc, Theravance, Inc., and Pfizer, Inc. amongst many others.

Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3572

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com/

0 notes

coolvoidunknown-blog · 6 years

Text

Chlamydia Infection Diagnostics and Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Market Outline: Chlamydia Infection Diagnostics and Therapeutics Market

Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to baby at birth. Chlamydia infection usually doesn’t have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in lower abdomen, pelvis, testicle or vagina and may also have eye discharge or spotting. Treatment may include antibiotics, anti-inflammatory agents, and hospital stay may be required.

Market Dynamics: Chlamydia Infection Diagnostics and Therapeutics Market

Global chlamydia infection diagnostics and therapeutics market is mainly driven by increase in prevalence of sexually transmitted diseases worldwide. Furthermore, emergence of rapid test and advances in biotechnology are expected to boost the chlamydia infection diagnostics and therapeutics market. In addition, increase in R&D activities towards development of therapeutics for antibiotic-resistant bacteria and initiatives by government and non-government agencies (such as World Health Organization (WHO) to increase awareness about STD’s and their symptoms are expected to bolster the chlamydia diagnostics and therapeutics market during the forecast period. However, high cost of development, stringent regulatory procedures for the approval and bacterial drug resistance is expected to hamper the chlamydia infection diagnostics and therapeutics market.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx

Market Scope: Chlamydia Infection Diagnostics and Therapeutics Market

Global chlamydia infection diagnostics and therapeutics market is segmented into diagnostics, therapeutics type, and end user type

Based on diagnostics, market is segmented into

· Direct Fluorescent Tests

· Nucleic Acid Amplification Tests

· Others

Based on therapeutics, market is segmented into

· Antibiotics

o Tetracyclines

o Macrolides

o Quinolones

o Others

· Others

Based on end user, market is segmented into

· Hospitals and Hospital Pharmacies

· Retail Pharmacies

· Others

Based on geography, market is segmented into

· North America

· Asia Pacific

· Europe

· Middle East and Africa

· Latin America

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-c654SbFYO64MsOhu

Market overview: Chlamydia Infection Diagnostics and Therapeutics Market

Global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to prevalence rate of sexually transmitted diseases. According to World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimate of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of the new ways to detect chlamydia infection in initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched cobas 6800/8800 systems for detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.

Region Overview: Chlamydia Infection Diagnostics and Therapeutics Market

Geographically, chlamydia infection diagnostics and therapeutics market is segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America market is expected to grow at significant rates owing to well-established healthcare infrastructure, presence of more number of market players and increase in awareness in related to early detection and treatment of sexually transmitted diseases. According to Centre for Disease Control and Prevention (CDC) in 2014, a total number of 1,441,789 chlamydia infections were reported to CDC in 50 states and District of Columbia in the United States. Europe chlamydia infection diagnostics and therapeutics market is expected to grow at notable rates owing to factors such as developed healthcare infrastructure and growing awareness related to STI’s. Asia Pacific market growth is attributed to developing infrastructure and prevalence of the chlamydia sexually transmitted diseases. According to World Health Organization, “Global incidence and prevalence of selected curable sexually transmitted infections – 2008”, in South East Asia region estimated that 8 million adults were infected with Chlamydia in 2008.

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-14mlyhjMGhVjZqa3

Competition Assessment: Chlamydia Infection Diagnostics and Therapeutics Market

Some of the players in chlamydia infection diagnostics and therapeutics market are Novartis AG (Switzerland), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), The Danaher Corporation (U.S.), Abbott Laboratories (U.S.), bioMérieux (France), Siemens AG (Germany), DiaSorin SpA (Italy), Becton Dickinson and Company (U.S.), and Thermo Fisher Scientific (U.S.)

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/

0 notes